27 September 2023
Novartis expects to complete the previously announced separation of Sandoz on October 4th, 2023.
Sandoz is a global leader in generic pharmaceuticals and biosimilars
Novartis shareholders will receive one share of Sandoz for every five shares of Novartis.
Etalon Capital, Inc. provides independent research with a focus on event-driven value equities to institutional investors. Events include M&As, spin-offs, activist investors, IPOs, SPACs, buybacks, recapitalizations, asset sales, hedge fund holdings, and other significant corporate transactions. These are diversified by sources of risk as well as risk/return profiles. We generate an edge with a unique research process, combining value, focus on corporate events, and story investing principles.